An Aptamer-based, Fluorescent and Radionuclide Dual-modality Probe
Overview
Affiliations
Aptamers which are promising and effective molecular probes, can deliver either fluorescent materials or radionuclides to tumors. This study aimed to develop a novel both fluorescent and radionuclide dual-modality probe based on a truncated aptamer and evaluate its stability and binding affinities in vitro. The aptamer JHIT2 with binding specifically to HepG2 cells was previously generated by Cell-SELEX. Using mfold and RNAstructure software to predict the secondary structure folded by a middle random sequence to truncate the primer sequences at both ends of the aptamer JHIT2 to yield the aptamer JHIT2e, with a similar secondary structure to JHIT2 and the same specificity and affinity as JHIT2. Attaching carboxyfluorescein (FAM) readily to the aptamer JHIT2e and then attaching iodine-131 to the FAM moiety which has multiple sites for iodine labeling to develop a novel both fluorescent and radionuclide dual-modality probe, termed I-FAM-JHIT2e. Cell uptake and fluorescence imaging assays in vitro confirmed that I-FAM-JHIT2e had both FAM fluorescence signal and radio-activity signal and maintained specific binding ability to the human hepatoma cell line HepG2. This work formed a basis for aptamer-based, dual-modality imaging probe that contains both fluorescent and radionuclide tags, which also is potential for theranostics.
The application of radionuclide therapy for breast cancer.
Musket A, Davern S, Elam B, Musich P, Moorman J, Jiang Y Front Nucl Med. 2024; 3:1323514.
PMID: 39355029 PMC: 11440853. DOI: 10.3389/fnume.2023.1323514.
Aptamer-decorated nanocarriers for viral adsorption: A special look at COVID-19.
Handali S, Rezaei M Mol Ther Nucleic Acids. 2024; 35(3):102310.
PMID: 39281706 PMC: 11401170. DOI: 10.1016/j.omtn.2024.102310.
Aptamers in neuro-oncology: An emerging therapeutic modality.
Doherty C, Wilbanks B, Khatua S, Maher 3rd L Neuro Oncol. 2023; 26(1):38-54.
PMID: 37619244 PMC: 10768989. DOI: 10.1093/neuonc/noad156.
Luminescent Aptamer-Based Bioassays for Sensitive Detection of Food Allergens.
Calabria D, Zangheri M, Shariati Pour S, Trozzi I, Pace A, Lazzarini E Biosensors (Basel). 2022; 12(8).
PMID: 36005040 PMC: 9405952. DOI: 10.3390/bios12080644.
Aptamer‑based therapy for targeting key mediators of cancer metastasis (Review).
Alhamhoom Y, As Sobeai H, Alsanea S, Alhoshani A Int J Oncol. 2022; 60(6).
PMID: 35425991 PMC: 9015191. DOI: 10.3892/ijo.2022.5355.